Rhythm Pharmaceuticals Inc. RYTM

NAS: RYTM | ISIN: US76243J1051   2/06/2025
63,66 USD (+3,80%)
(+3,80%)   2/06/2025

4 april 2023 · Rhythm Pharmaceuticals kondigt overname aan van Xinvento B.V. en portfolio van Investigational Therapeutics · Persbericht

27 februari 2023 · Rhythm Pharmaceuticals Announces Acquisition of Xinvento B.V. and Portfolio of Investigational Therapeutics · Persbericht

6 september 2022 · Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Granted Marketing Authorization by European Commission for Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome · Persbericht

22 juli 2022 · Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼¹ IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Bardet-Biedl Syndrome · Persbericht

20 juli 2022 · Rhythm Pharmaceuticals Announces Early Access Authorization for Setmelanotide for Use in Patients with Bardet-Biedl Syndrome in France · Persbericht

9 maart 2021 · Rhythm Pharmaceuticals Announces Late-Breaking Data Presentations at ENDO 2021 · Persbericht

1 maart 2021 · Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results · Persbericht

10 februari 2021 · Rhythm Pharmaceuticals, Inc. Announces Closing of $172.5 Million Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares · Persbericht

5 februari 2021 · Rhythm Pharmaceuticals, Inc. Announces Pricing of Public Offering · Persbericht

3 februari 2021 · Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering · Persbericht

5 januari 2021 · Rhythm Pharmaceuticals Announces Sale of Priority Review Voucher for $100M · Persbericht

5 januari 2021 · Pharvaris Expands Board of Directors with Appointment of David Meeker, M.D., as Chair and Robert Glassman, M.D., as Director · Persbericht

Mijn selecties